Logo
Global Pharmacogenomics Market 2020-2030

Global Pharmacogenomics Market 2020-2030

Bonafide Trust 28-09-2020 181 Pages Figures : 83 Tables : 88
Region : Global Category : Lifescience Biotechnology

Global pharmacogenomics market will reach $12.83 billion by 2030, growing by 8.1% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic. Highlighted with 88 tables and 83 figures, this 181-page report “Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Region. Based on Service, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Genotyping • SNP Identification • Diagnostics • Other Services Based on Technology, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Polymerase Chain Reaction (PCR) • Microarray • Sequencing • Electrophoresis • Mass Spectrometry • Other Technologies Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oncology • Infectious Diseases • Neurology/Psychiatry • Cardiovascular • Pain Management • Other Applications Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals and Clinics • Pharmaceutical Companies • Research Institutes Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) • North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (Saudi Arabia, UAE, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Service, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in global pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): 23andMe, Inc. Abbott Laboratories Admera Health, LLC Agena Biosciences, Inc. Astra Zeneca PLC Bayer AG Becton, Dickinson and Company Cancer Genetics, Inc. Dynamic DNA Laboratories Empire Genomics LLC F. Hoffmann-La Roche Ltd geneOmbio Technologies Pvt Ltd. Genomic Health, Inc. Illumina, Inc. Laboratory Corporation of America Holdings Myriad Genetics Inc. Oneome LLC Opko Health, Inc. Pathway Genomics Corporation QIAGEN N.V. Quest Diagnostics Incorporated Teva Pharmaceuticals Industries Ltd. Thermo Fisher Scientific Inc. Transgenomic, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Read More

Card image cap

Interested in this report?
Get your FREE sample!

Requirement Gathering & Methodology
Data Collection Techniques
Our Research Team & Data Sourcing
Data Science & Analytical Tools
Data Visualization & Presentation Skills
Project/ Report Delivery & After Sales Services